On Feb 12, AVEO is set to present overall survival data for Tivozanib for the treatment of renal cancer. This study is designed to go head to head with an active control. If result is favorable look for a pop up in price. I just bought a few shares ($7.55) with my spare change. I figure if insders have been buying and AVEO have already hired a sales force although FDA approval is not expected until June, heck why not take a chance. Please do your own due dilegience. Here is a quick summary to bring you up to date with AVEO... http://www.seekingalpha.com/article/1054881-aveo-pharmaceuticals-a-hidden-gem-or-a-hidden-disaster
Anything is possible, but the data tommorow rates to be a minor event.
They already provided early one year survival. This was obviously not good (78% to 81% the wrong way), but the management presented a very clear case why the strong cross-over effect could create such data. Even AF thought this was a fine explanation.
Unless the data has changed significantly (possible, but unlikely) all we will get is more "meat". Hopefully we will see an OS curve that start out strong, then crosses over just before 1 year. It is possible that such a curve could yield a decent HR, but that seams unlikely as management failed to provide any hint of such (and it would likely be present even in early data).
My magic coin says 30% pleasent surprise, 50% snoze on 'till FDA time, 20% eek!.